Nov. 22, 2002 — Dendritic Nanotechnologies Ltd. (DNT) has named Charles Burke founding chief executive officer.
Burke spent 15 years at Abbott Laboratories, where he created and led a group responsible for developing diagnostic products. He also was CEO of Research Biochemicals Inc., as well as founder and president of Monument Partners Inc.
He will be based in the Michigan laboratories of DNT, a U.S. subsidiary of Australian pharmaceutical nanotechnology firm Starpharma Pooled Development Ltd. The research facilities are located in the Center for Applied Research & Technology at Central Michigan University.
DNT is a leading patent holder in pharmaceutical products from dendrimers, synthetic polymers with branching parts designed as nanoscale vehicles for delivering drugs.